Qyuns Therapeutics Co., Ltd.

Current Location：Home Investor RelationsDisclosure

Announcements and Circulars

292024.05
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLMENT FOR QX005N PHASE III CLINICAL TRIAL FOR THE TREATMENT OF PRURIGO NODULARIS

Show More
162024.05
CLARIFICATION ANNOUNCEMENT SUPPLEMENTAL NOTICE AND REVISED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 31, 2024

Show More
142024.05
REVISED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 31, 2024

Show More
142024.05
SUPPLEMENTAL NOTICE OF 2023 ANNUAL GENERAL MEETING

Show More
092024.05
VOLUNTARY ANNOUNCEMENT QYUNS OBTAINED IND CLEARANCE FOR QX013N FOR TREATMENT OF CHRONIC SPONTANEOUS URTICARIA IN CHINA

Show More
072024.05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

Show More

11 12 13